News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Impulse Dynamics secures $30m for novel heart implant Chronic heart failure (CHF) device specialist Impulse Dynamics has secured £30 million in financing.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
